Radiopharmaceutical firm Draxis Health reported fourth-quarter revenues from continuing operations of $9.8 million (U.S.), compared with $8.9 million posted in the same period last year. For the year (end-December 31, 2002), the Mississauga, Ontario-based firm had revenues from continuing operations of $38.6 million, up 14% over 2001 revenues of $33.9 million.
Net income stood at $709,000 for the quarter, compared with $613,000 for the same period last year. For the year, the firm reported net income of $2.1 million compared with a loss of $1.5 million in 2001. Draxis Health attributed its gains to increased penetration of radiopharmaceutical products into the U.S., plus higher royalty and licensing revenues.
By AuntMinnie.com staff writersFebruary 6, 2003
Related Reading
DraxImage gets clearance for radiotherapeutic kit, January 29, 2003
Cytogen, Draxis dispute heats up, January 28, 2003
Production of palladium BrachySeed version halted, January 17, 2003
Draxis Health starts phase I trials, January 9, 2003
Draxis Health’s Q3 revenues climb 10%, November 14, 2002
Copyright © 2003 AuntMinnie.com
